NEW YORK, April 11 - Swedish mass-spec company Gyros today said it has closed an additional $6 million in its second private-equity round of financing, bringing to $36 million the total second-round booty.
Gyros recently unveiled its Gyrolab MALDI SP1 and Gyrolab Workstation, both of which will be shown off at a number of meetings in the US and Europe in the coming months.
In January, Gyros said it and ACE BioSciences plan to test its new technique for miniaturizing and automating sample preparation for protein identification.
The Gyros system is designed to automate sample prep for MALDI mass spectrometry and boost sensitivity in protein identification. It is a new application of the company's core platform, by which laboratory processes are miniaturized and embedded into CDs for parallel preparation and processing.
Gyros, based in Uppsala, was spun off from Amersham Pharmacia Biotech in 2000.